Group 1 - The board of directors of Gansu Longshen Rongfa Pharmaceutical Co., Ltd. held its 20th meeting on August 22, 2025, where all 9 directors attended, and the meeting was deemed legal and effective [1] - The board approved the 2025 semi-annual report, confirming that it accurately reflects the company's operational status for the first half of 2025, with no false statements or omissions [2][3] - The company reported a net profit attributable to shareholders of 27,956,129.83 yuan for the first half of 2025, with retained earnings of 263,988,424.28 yuan in the consolidated report [2] Group 2 - The board proposed a profit distribution plan for the first half of 2025, recommending a cash dividend of 0.20 yuan per 10 shares, totaling 6,066,900.00 yuan, with no stock dividends or capital reserve transfers [3] - The board agreed to adjust the expected daily related transactions for 2025 based on actual operational needs, which has been approved by the independent directors and the audit committee [4] - The board approved the establishment of a temporary management system for information disclosure exemptions and the revision of several internal management systems, including those for directors and senior management shareholdings [5]
陇神戎发: 董事会决议公告